In May 2025, India’s agriculture minister released the country’s first genome-edited rice varieties — DRR Dhan 100 (Kamala) and Pusa DST Rice 1 — developed by ICAR using CRISPR-Cas9 without introducing any foreign DNA. Field evaluations across multiple agroecological zones showed a mean yield increase of 19% for Kamala over the Samba Mahsuri parent variety, with earlier maturity by up to 20 days (ICAR-IIRR, May 2025). Pusa DST Rice 1 showed yield gains of 10–30% higher under drought and saline stress conditions compared to its parent variety, MTU 1010 (ICAR-IARI, May 2025). These are not projections. They are the results of national multi-site field trials, and they reframe the conversation about CRISPR drought tolerance from research pipeline to procurement consideration.

What CRISPR Gene Editing Actually Does — and Doesn’t Do

CRISPR-Cas9 allows researchers to make precise, targeted changes to a crop’s existing DNA at specific gene loci — without inserting genetic material from another species. This is the technical distinction that separates it from transgenic GMOs and that has driven regulatory divergence globally. When applied to drought tolerance, edits typically target genes that regulate stomatal density, water-use efficiency, or root architecture. India’s Pusa DST Rice 1 had its DST (Drought and Salinity Tolerance) gene precisely edited to enhance stress resistance, resulting in reduced stomatal density and improved water use alongside improved yield (ICAR-IARI, 2025).

Because no foreign DNA is present in the final product, genome-edited crops are treated differently from GMOs in several jurisdictions. India exempted both released varieties from its Environment Protection Act biosafety rules. Argentina has allowed non-transgenic gene-edited crops since 2015 under its CONABIA process — the first country in the world to do so — and remains among the most permissive regulatory environments globally (npj Science of Plants, February 2026). The EU position remains under consultation, with a two-tier proposal under discussion for simple versus complex edits. England, following its departure from the EU, became the only European jurisdiction to allow gene-edited plants for any use as of 2025 (npj Science of Plants, February 2026).

Comparison Table: Crop Gene Editing vs Other Breeding Approaches

What the Verified Field Data Shows

The two ICAR varieties released in May 2025 are the most clearly documented case of CRISPR drought-tolerance results entering commercial-scale consideration as of 2026.

DRR Dhan 100 (Kamala), developed by ICAR-IIRR in Hyderabad, targeted the CKX2 (cytokinin oxidase) gene to increase grain number per panicle. Multi-site field evaluations showed a mean yield of 53.7 quintals per hectare, with a maximum recorded yield of 88.96 quintals per hectare, against a mean increase of 19% over the parent Samba Mahsuri variety. The variety matures approximately 20 days earlier, reduces methane emissions, and performs under low nitrogen inputs — properties relevant to both climate resilience and input cost management (ICAR-IIRR, May 2025). Modelling by ICAR suggests that if cultivated across 5 million hectares, these varieties could produce 4.5 million additional tonnes of paddy and reduce greenhouse gas emissions by approximately 32,000 tonnes, or 20% (ICAR press note, May 2025).

Pusa DST Rice 1, developed by ICAR-IARI in New Delhi from the Cotton Dora Sannalu (MTU 1010) variety, showed yield gains of 10–30% higher under drought and saline stress conditions compared to its parent, across trial locations spanning Andhra Pradesh, Telangana, Karnataka, Tamil Nadu, Odisha, and other states (ICAR, May 2025).

For maize, CRISPR research has identified relevant drought tolerance targets. A January 2025 study from Jilin Agricultural University demonstrated that editing the ZmPL1 gene improved drought tolerance in maize under managed stress conditions (GM Crops & Food, January 2025). CIMMYT continues to develop climate-adaptive maize germplasm, though its primary drought-tolerance work in Africa and Asia to date has used conventional and marker-assisted breeding rather than CRISPR specifically — the CRISPR pipeline for maize is active in research but not yet at the commercial field trial scale India’s rice programme has reached.

The Regulatory Map: Where CRISPR Crops Can Move to Market

The regulatory landscape as of early 2026 is fragmented in ways that directly shape where CRISPR drought-tolerant crops can enter procurement cycles.

Permissive jurisdictions — Argentina (since 2015), India (2025 exemption framework), Japan, Australia, and England — treat non-transgenic gene-edited crops under conventional breeding rules or simplified review processes. Argentina was the first country globally to formally determine that SDN-1 edits without foreign DNA do not require GMO-level biosafety assessment (npj Science of Plants, February 2026). India’s May 2025 release of DRR Dhan 100 and Pusa DST Rice 1 under its simplified framework represents the most significant recent commercial step.

Jurisdictions under active discussion — the EU (37 countries currently debating their position), Indonesia, South Korea, and several African countries including Uganda, Mozambique, and Mauritius — have regulatory processes underway but no final framework as of early 2026.

Restrictive jurisdictions — including Peru, which has a GMO moratorium through 2035 — treat gene-edited crops as GMOs regardless of transgenic status.

For operators and procurement teams, this map defines where CRISPR-edited seed can legally enter planting schedules and where regulatory clearance remains a multi-year variable.

Access, IP, and the Smallholder Question

India’s ICAR varieties are publicly developed and released through the national seed system — a significant difference from proprietary commercial gene-editing pipelines. This means both DRR Dhan 100 and Pusa DST Rice 1 are intended for broad farmer access rather than commercial licensing, and their costs should track conventional certified seed pricing rather than a technology premium.

The access dynamic changes significantly for proprietary commercial pipelines. Corteva offers a bundle licensing approach for CRISPR-Cas9 plant agriculture that includes separate tracks for internal R&D, commercial seed, and academic research (PMC analysis of CRISPR IP, 2023). For African smallholder contexts specifically, IP litigation and licensing costs have delayed access to gene-editing technologies — a structural barrier that public-sector development programmes at CGIAR centres are working to address. CGIAR’s use of gene editing for crop and livestock improvement is explicitly positioned as a non-controversial alternative to transgenic approaches, precisely because the non-transgenic character of SDN-1 edits avoids the regulatory and public acceptance issues that slowed GMO adoption in Africa (Cornell University/TCI, September 2025).

What This Means for Procurement and Farm Operations

The technology threshold has been crossed at the research and regulatory level in India, with multi-site field data and a national regulatory exemption both now in place. The operational implications differ by geography and operator type:

• In India, CRISPR-edited rice varieties are available for Kharif planting cycles under the national seed distribution system. Procurement officers at the state level now have verified yield and water-use data from national trials to inform varietal selection decisions.

• In Argentina and other permissive jurisdictions, the regulatory pathway for commercial CRISPR seed is established, and the pipeline from commercial breeding programmes to commercial entry is measurably shorter than for transgenic alternatives.

• In the EU, Africa (outside a handful of jurisdictions), and most of Southeast Asia, operators face regulatory timelines that are not yet resolved — meaning CRISPR drought-tolerant varieties are a procurement option to plan for, not an immediate procurement decision.

• For large-acreage commercial operators in permissive jurisdictions, the 10–30% yield stability improvement under drought stress documented in India’s national trials represents a risk-management calculation, not just an agronomic one: water input costs and yield loss exposure under terminal drought are now quantifiable against seed cost differential.

FAQs

Is CRISPR gene editing the same as GMO? No. CRISPR as used in the crops discussed here (SDN-1 and SDN-2 methods) introduces targeted changes to the plant’s existing DNA without inserting genes from other species. This is the technical basis on which India, Argentina, and other jurisdictions have exempted these varieties from GMO biosafety rules. Traditional GMOs insert foreign DNA — a different process with a different regulatory and public acceptance profile.

What yield improvements have been verified in CRISPR drought-tolerant rice? India’s ICAR released two varieties in May 2025 with verified field trial results. DRR Dhan 100 (Kamala) showed a 19% mean yield increase over its parent variety across multi-site national trials (ICAR-IIRR, 2025). Pusa DST Rice 1 showed 10–30% higher yield under drought and saline stress conditions compared to its parent (ICAR-IARI, 2025).

Which countries allow CRISPR-edited crops for commercial planting? As of early 2026: Argentina (since 2015), India (2025, rice varieties released), Australia (since 2019), Japan, and England. Several other countries are in active regulatory review. The EU has not finalised its framework; most African countries have no specific regulation, with a small number in formal review processes.

How long does CRISPR crop development take compared to conventional breeding? Depending on the crop and the trait, CRISPR editing can compress the development timeline from 10–20 years for conventional breeding to 3–7 years, primarily by enabling precise targeted changes without the multi-generational backcrossing required to introgress traits from wild relatives or donor lines. The regulatory review period then adds variable time depending on jurisdiction.

What crops are furthest along in CRISPR drought tolerance programmes? Rice has the most advanced public-sector field data and commercial release as of 2026, led by India’s ICAR. Maize CRISPR drought research is active at the laboratory and early trial level (Jilin Agricultural University, 2025; CIMMYT breeding pipeline). Groundnut and sorghum programmes at ICRISAT are in development. Wheat CRISPR drought work including root architecture editing is at research stage (TaRPK1 gene targeting, 2024).

What are the main risks operators should be aware of? Three primary risk categories: (1) off-target edits — current published data shows rates below 0.14% in released lines, with ongoing monitoring required across seasons; (2) regulatory jurisdiction risk — seed cleared in one country may not be plantable in another, creating supply chain planning complexity for cross-border operations; (3) IP and access constraints — proprietary commercial lines may carry licensing costs that affect total input economics, particularly for smallholder programmes in Africa.

Market Implication

India’s May 2025 release of the world’s first genome-edited rice varieties under a simplified national regulatory framework is the single most operationally significant CRISPR-in-agriculture event of the last decade. It is not a proof-of-concept. It is a national field-tested, multi-site validated, commercially released product — and its regulatory status resolves the question of whether CRISPR drought traits can reach farm-scale deployment outside of proprietary commercial pipelines. The procurement question for operators in permissive jurisdictions has shifted from “when will this be ready” to “what does the varietal performance data require us to consider.” The question for operators in restrictive or undecided jurisdictions is how long their regulatory lag will cost them in yield under worsening drought conditions.

Sources

1. ICAR-IIRR, “DRR Dhan 100 (Kamala) national field trial results,” May 2025

2. ICAR-IARI, “Pusa DST Rice 1 field evaluation data,” May 2025

3. ICAR press note, “India’s First Genome-Edited Rice Varieties,” May 4, 2025

4. Nature, “India approves first genome-edited rice varieties,” d44151-025-00078-2, May 2025

5. Mongabay India, “India releases genome-edited rice, draws both applause and alarm,” June 2025

6. npj Science of Plants, “Global status of genome editing versus transgenesis legislation in plants,” February 2026

7. Wang et al., “CRISPR-Cas9-mediated editing of ZmPL1 gene improves tolerance to drought stress in maize,” GM Crops & Food, January 2025

8. Cornell University/TCI, “Can Gene-Edited Crops Revolutionize Agriculture in Developing Countries?”, September 2025

9. PMC, “Assessing agricultural gene editing regulation in Latin America,” 2023

10. Innovative Genomics Institute, “CRISPR in Agriculture: 2024 in Review,” May 2025